Eli Lilly & Co. New York Stock Exchange
Open: $221.45 High: $239.37 Low: $217 Close: $233.98
Range: 2021-06-23 - 2021-06-24
Volume: 12,055,278
Market: Open
Powered by Finage Stock APIDelayed data
Eli Lilly & Co. Lilly Corporate Center Indianapolis IN, 46285 http://www.lilly.com
Eli Lilly and Co is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. It discovers, develops, manufactures, and sells human pharmaceutical products and animal health products.
  • CEO: David A. Ricks
  • Employees: 40,655
  • Sector: Healthcare
  • Industry: Drug Manufacturers
LLY News
Latest news about the LLY
  • Lilly Stock Hits Record High On Key Alzheimer's Win, Looking To Follow Biogen

    Eli Lilly's experimental Alzheimer's treatment snagged a key FDA designation on Thursday. LLY stock surged to a record high.

    View More →
  • US STOCKS-Nasdaq, S&P 500 scale new peak as jobs recovery gains traction

    The Nasdaq and the S&P 500 indexes hit all-time highs on Thursday, boosted by shares of Tesla and other top-shelf technology firms as data showing fewer weekly jobless claims bolstered views of a steady recovery in the labor market. Focus was also on President Joe Biden's meeting with a bipartisan group of U.S. senators at 11:45 a.m. ET to discuss their proposed framework for a spending bill to invest in the country's bridges, roads and other physical infrastructure.

    View More →
  • Why Eli Lilly Stock Is Soaring Today

    What happened Shares of Eli Lilly (NYSE: LLY) were soaring 7.8% higher at 11:05 a.m. EDT on Thursday. The big gain came after the drugmaker announced that the U.S. Food and Drug Administration (FDA) had granted Breakthrough Therapy designation to Lilly's experimental Alzheimer's disease drug donanemab.

    View More →
  • The Alzheimer’s Drug Floodgates Are Opening. Eli Lilly Has Positive News.

    The drug maker Eli Lilly said the FDA designated its Alzheimer's drug candidate as a breakthrough therapy. It will file for approval later this year.

    View More →
  • Dow Jones Today Jumps; Nasdaq, S&P 500 Ace New Highs As Tesla, Snap, Celsius Rally; Eli Lilly Gets FDA Alzheimer's Nod

    Tesla, Snap and Eli Lilly punched higher, and stocks opened in rally mode Thursday as infrastructure negotiations progressed.

    View More →
  • US STOCKS-Nasdaq set for record open as jobs recovery gains traction

    The Nasdaq was set to open at a record high on Thursday, boosted by shares of Tesla and other top-shelf technology firms as data showing fewer weekly jobless claims pointed to a steady recovery in the labor market. Tesla Inc rose 2.8% after Chief Executive Officer Elon Musk said he would list SpaceX's space internet venture, Starlink, when its cash flow is reasonably predictable, adding that Tesla shareholders could get preference in investing.

    View More →
  • Eli Lilly Jumps, Dollar Tree Slips as Stock Market Chases Infrastructure Plan Higher

    Stocks set for a higher open as lawmakers are signaling that an infrastructure deal could get done soon.

    View More →
  • 5 Top Stock Gainers for Thursday: Marin Software, Tesla, Eli Lilly

    Stocks climbed Thursday after the number of Americans filing for first-time unemployment benefits fell last week and durable-goods orders climbed at the fastest pace this year. Marin Software surged after saying its ad management platform now lets users manage Instacart ads. Instacart is an online platform that delivers groceries and other items from nearly 55,000 stores in the U.S. and Canada.

    View More →
  • Pharma Stock Roundup: EU Nod to AZN, SNY, JNJ Drugs, Glaxo's New COVID-19 Drug Data

    EU approves AstraZeneca's (AZN) rare disease drug, Koselugo and expanded use of J&J's (JNJ) Darzalex Faspro and Sanofi's (SNY) Aubagio.

    View More →
  • Lilly announces call for Leonard Award nominations as part of global initiative celebrating 100 years of insulin

    In honor of the 100th anniversary of the discovery of insulin, Eli Lilly and Company (NYSE: LLY) today launched the Leonard Award to recognize diverse champions dedicated to advancing diabetes management through innovative thinking and novel approaches. Nominations are being accepted now until August 31, 2021 at Lilly.com/LeonardAward.

    View More →
  • UPDATE 3-Lilly to seek accelerated FDA approval for Alzheimer's drug this year

    Eli Lilly and Co said it will seek accelerated approval from the U.S. health regulator this year for its Alzheimer's candidate, weeks after a rival drug from Biogen Inc won the agency's endorsement using the same regulatory pathway. Lilly's shares jumped over 8% on Thursday, while Biogen fell nearly 5%. Biogen's Aduhelm was approved under the FDA's accelerated approval program that allows certain drugs on the market earlier based on evidence they can likely benefit patients.

    View More →
  • Eli Lilly Soars as Alzheimer’s Therapy Gets FDA’s Breakthrough Tag

    By Dhirendra Tripathi

    View More →
  • Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease

    The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company's (NYSE: LLY) investigational antibody therapy for Alzheimer's disease (AD). The Breakthrough Therapy designation aims to expedite the development and review of drugs that are intended to treat a serious condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over already available th

    View More →
  • Lilly Gets FDA Breakthrough Status for Alzheimer's Drug

    Eli Lilly received FDA breakthrough status for its donanemab Alzheimer's drug, speeding the agency's review of the product. The shares are higher.

    View More →
  • Premarket Movers Thursday: Rite Aid, Marin Software, Eli Lilly

    Stocks moving in premarket trading Thursday include Rite Aid, Marin Software, Eli Lilly, KB Home and Roku.

    View More →
  • Eli Lilly, Accenture Rise Premarket; Beyond Meat Falls

    By Peter Nurse

    View More →
  • Eli Lilly and Company's (NYSE:LLY) Intrinsic Value Is Potentially 34% Above Its Share Price

    Today we will run through one way of estimating the intrinsic value of Eli Lilly and Company ( NYSE:LLY ) by taking the...

    View More →
  • Dual-Antibody Cocktail Shows Effectiveness In COVID-19 Animal Models: Reuters

    In mice and hamster study, COVID-19 therapies comprising two types of antibodies were found to be effective against a wide range of COVID-19 variants, Reuters reported citing the Washington University School of Medicine. The latest study included three of the four variants that have been designated "variants of concern" by the WHO. The FDA in April revoked the emergency use authorization of Eli Lilly And Co's (NYSE: LLY) single antibody therapy, bamlanivimab, amid resistance due to the variants.

    View More →
  • Roche's Alzheimer's Antibody Reduces Associated Biomarkers In Subset Of AD Patients, Study Shows

    Experimental anti-amyloid antibodies from Eli Lilly & Co (NYSE: LLY) and Roche Holding AG's (OTC: RHHBY) failed to improve symptoms of Alzheimer's disease (AD) in a Phase 2/3 study led by Washington University School of Medicine reported last year. Now, the study researchers say they have evidence that Roche's gantenerumab could help a subset of patients. In trial participants with dominantly inherited Alzheimer's disease (DIAD), which causes early onset of memory loss and other symptoms, Roche'

    View More →
  • Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?

    Style Box ETF report for FLQL

    View More →